How many drugs treat Alzheimer's disease?

Drug Landscape tracks 10 marketed treatments for Alzheimer's disease (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/alzheimer-s-disease.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Alzheimer's disease — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Alzheimer's disease (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Alzheimer's disease, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Neuraceq	FLORBETABEN	Life Molecular	Radioactive Diagnostic Agent [EPC]		2025-01-01
Leqembi	LECANEMAB	Eisai	Amyloid Beta-directed Antibody [EPC]	Amyloid beta A4 protein	2023-01-01
Aduhelm	ADUCANUMAB	Biogen	Amyloid Beta-directed Antibody	Amyloid beta A4 protein	2021-01-01
Vizamyl	FLUTEMETAMOL	Ge Healthcare	Radioactive Diagnostic Agent [EPC]		2013-01-01
Amyvid	FLORBETAPIR	Avid Radiopharms Inc	Radioactive Diagnostic Agent [EPC]		2013-01-01
Razadyne	GALANTAMINE	Johnson & Johnson	Cholinesterase Inhibitor	Acetylcholinesterase	2001-01-01
Aricept	DONEPEZIL	Eisai	Cholinesterase Inhibitor	Sigma non-opioid intracellular receptor 1	1996-01-01
ADUHELM	ADUCANUMAB-AVWA	BIOGEN INC		Amyloid beta A4 protein
LEQEMBI	LECANEMAB-IRMB	EISAI INC	Amyloid Beta-directed Antibody [EPC]	Amyloid beta A4 protein
Aricept	Aricept	Eisai Korea Inc.		Beta-secretase 1, Multidrug resistance protein 1, Acetylcholine receptor subunit epsilon

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 4 drugs in Alzheimer's disease
Eisai · 2 drugs in Alzheimer's disease
BIOGEN INC · 1 drug in Alzheimer's disease
Biogen · 1 drug in Alzheimer's disease
EISAI INC · 1 drug in Alzheimer's disease
Eisai Korea Inc. · 1 drug in Alzheimer's disease
Ge Healthcare · 1 drug in Alzheimer's disease
Johnson & Johnson · 1 drug in Alzheimer's disease
Life Molecular · 1 drug in Alzheimer's disease
Novartis · 1 drug in Alzheimer's disease
US Department of Veterans Affairs · 1 drug in Alzheimer's disease
University of Virginia · 1 drug in Alzheimer's disease

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Alzheimer's disease:

Cite this brief

Drug Landscape (2026). Alzheimer's disease — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/alzheimer-s-disease. Accessed 2026-06-10.

Alzheimer's disease full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing